Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „study“
Suchtreffer
Begriffe & Kennungen
Adcirca (previously Tadalafil Lilly) · 4.8 · In the pivotal placebo-controlled study of ADCIRCA for the treatment of PAH, a total of 323 patients were trea
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.8 · Post-marketing study in paediatric patients (H6D-JE-TD01) Safety data were collected during an observational p
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.8 · Post-marketing study in paediatric patients (H6D-JE-TD01) Safety data were collected during an observational p
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.8 · Uncontrolled pharmacokinetic study in paediatric patients (H6D-MC-LVIG) In a paediatric multiple ascending dos
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.8 · Uncontrolled pharmacokinetic study in paediatric patients (H6D-MC-LVIG) In a paediatric multiple ascending dos
Eintrag öffnenAdempas · 4.5 · Nitrates In a clinical study the highest dose of riociguat (2.5 mg tablets 3 times daily) potentiated the bloo
Eintrag öffnenAdempas · 4.5 · Nitrates In a clinical study the highest dose of riociguat (2.5 mg tablets 3 times daily) potentiated the bloo
Eintrag öffnenAdenuric · 4.5 · Desipramine/CYP2D6 substrates Febuxostat was shown to be a weak inhibitor of CYP2D6 in vitro. In a study in he
Eintrag öffnenAdenuric · 4.5 · Desipramine/CYP2D6 substrates Febuxostat was shown to be a weak inhibitor of CYP2D6 in vitro. In a study in he
Eintrag öffnenAdenuric · 4.5 · Rosiglitazone/CYP2C8 substrates Febuxostat was shown to be a weak inhibitor of CYP2C8 in vitro. In a study in
Eintrag öffnenAdenuric · 4.5 · Rosiglitazone/CYP2C8 substrates Febuxostat was shown to be a weak inhibitor of CYP2C8 in vitro. In a study in
Eintrag öffnenAdenuric · 4.5 · Theophylline An interaction study in healthy subjects has been performed with febuxostat to evaluate whether t
Eintrag öffnenAdenuric · 4.5 · Theophylline An interaction study in healthy subjects has been performed with febuxostat to evaluate whether t
Eintrag öffnenAdjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals) · 4.8 · 7 0.25 mL of Adjupanrix; in this study fever was common with no increase in incidence seen after the second pr
Eintrag öffnenAdjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals) · 4.8 · Similar reactogenicity results were obtained in a clinical study (D-PAN-H5N1-009) that was conducted in childr
Eintrag öffnenAdtralza · 4.5 · Immune responses to non-live vaccines were assessed in a study in which adult patients with atopic dermatitis
Eintrag öffnenAdtralza · 4.8 · In ECZTRA 1, ECZTRA 2, ECZTRA 3, and the vaccine-response study, the incidence of ADA up to 16 weeks was 1.4%
Eintrag öffnenAerius · 4.8 · A retrospective observational safety study indicated an increased incidence of new-onset seizure in patients 0
Eintrag öffnenAerius · 4.8 · A retrospective observational safety study indicated an increased incidence of new-onset seizure in patients 0
Eintrag öffnenAfqlir · 4.8 · Serious ocular adverse reactions in the study eye related to the injection procedure have occurred in less tha
Eintrag öffnen